Kardiovaskuläre Risiken von COX-2-Hemmern

Literatur (Weitere Literatur beim Verfasser)

• 1 Alsalameh S, Burian M, Mahr G, Woodcock B G, Geisslinger G. Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor.  Aliment Pharmacol Ther. 2003;  17 489-501
• 2 Bombardier C, Laine L, Reicin A. et al for the VIGOR Study Group . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 1520-1528
• 3 Farkouh M E, Korshner H, Harrington R A. et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), cardiovascular outcomes: randomised controlled trial.  Lancet. 2004;  364 675-684
• 4 FDA CLASS Advisory Committee .CLASS Advisory Committee briefing document. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_01_searle.pdf 2001
• 5 FitzGerald G A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease.  Nature Drug Disc. 2003;  2 879-890
• 6 FitzGerald G A. Coxibs and cardiovascular disease.  N Engl J Med. 2004;  351 1709-1711
• 7 John S, Schmieder R  E. Beeinflussen COX-2-Inhibitoren das kardiovaskuläre Risiko?.  Dtsch Med Wochenschr. 2002;  127 156-159
• 8 Jüni P, Rutjes A WS, Dieppe P A. Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs?.  Br Med J. 2002;  324 1287-1288
• 9 Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe P A, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.  Lancet. 2004;  364 4999-5007
• 10 Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.  Biochem Pharmacol. 2002;  63 817-821
• 11 Schnitzer T J, Burmester G R, Mysler E. et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), cardiovascular outcomes: randomised controlled trial.  Lancet. 2004;  364 665-674
• 12 Schwabe U. Paffrath D Arzneiverordnungsreport 2004,. Springer Verlag Berlin-Heidelberg-New York ISBN 3-540-21359-7
• 13 Zimmermann K C, Sarbia M, Schrör K, Weber A -A. Constitutive cyclooxygenase-2-expression in healthy human and rabbit gastric mucosa.  Mol Pharmacol. 1998;  54 536-540